2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
Such companies can be wonderful options for income-seeking investments. If you're in the market for that combo, let's ...
pharmaphorum9d
Novartis cues up Cosentyx as disease-modifying treatment for psoriasis
Novartis says Cosentyx could be used as an early intervention in psoriasis after new data suggests it is the first drug of its kind to modify the course of the disease. The Swiss big pharma ...
pharmaphorum6d
UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trial
The BE RADIANT trial pitted bimekizumab against Novartis’ Cosentyx (secukinumab) in the treatment of adults with moderate-to-severe psoriasis, and according to UCB is the first study to compare ...
Zacks.com on MSN2d
Novartis Posts Q4 Earnings and Sales Beat, Shares Gain
Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings ...
Pharmaceutical Technology14d
Interleukin inhibitors remain a strong growth driver in dermatology
If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.